Nuformix plc (NFX.L)
LSE · GBp · Healthcare · Biotechnology
£0.0963 (-3.70%) as of
Key statistics
- Market cap
- 2.51M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0940 – 0.5550
- Beta
- 1.55
- Profit margin
- 0.00%
- Volume
- 2.04M
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 3
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.